Filtered By:
Source: Circulation
Condition: Ischemic Stroke

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 235 results found since Jan 2013.

Amplatzer ™ amulet™ left atrial appendage occluder versus watchman™ device for stroke prophylaxis (amulet ide): a randomized controlled trial
Conclusions: The Amulet occluder was non-inferior for safety and effectiveness of stroke prevention for NVAF compared with the Watchman device, and superior for LAA occlusion. Procedure-related complications were higher with the Amulet device and decreased with operator experience. Clinical Trial Registration: URL https://clinicaltrials.gov Unique Identifier NCT02879448.PMID:34459659 | DOI:10.1161/CIRCULATIONAHA.121.057063
Source: Circulation - August 30, 2021 Category: Cardiology Authors: Dhanunjaya Lakkireddy David Thaler Christopher R Ellis Vijendra Swarup Lars Sondergaard John Carroll Michael R Gold James Hermiller Hans-Christoph Diener Boris Schmidt Lee MacDonald Moussa Mansour Brijeshwar Maini Laura O'Brien Stephan Windecker Amulet ID Source Type: research

Amplatzer ™ amulet™ left atrial appendage occluder versus watchman™ device for stroke prophylaxis (amulet ide): a randomized controlled trial
Conclusions: The Amulet occluder was non-inferior for safety and effectiveness of stroke prevention for NVAF compared with the Watchman device, and superior for LAA occlusion. Procedure-related complications were higher with the Amulet device and decreased with operator experience. Clinical Trial Registration: URL https://clinicaltrials.gov Unique Identifier NCT02879448.PMID:34459659 | DOI:10.1161/CIRCULATIONAHA.121.057063
Source: Circulation - August 30, 2021 Category: Cardiology Authors: Dhanunjaya Lakkireddy David Thaler Christopher R Ellis Vijendra Swarup Lars Sondergaard John Carroll Michael R Gold James Hermiller Hans-Christoph Diener Boris Schmidt Lee MacDonald Moussa Mansour Brijeshwar Maini Laura O'Brien Stephan Windecker Amulet ID Source Type: research

Effect of Rivaroxaban and Aspirin in Patients with Peripheral Artery Disease Undergoing Surgical Revascularization: Insights from the VOYAGER PAD Trial
Conclusions: The efficacy of rivaroxaban is associated with a benefit in surgical LER patients. While bleeding was increased with rivaroxaban plus aspirin, the incidence was low, with no significant increase in fatal bleeding, intracranial hemorrhage or postprocedural bleeds requiring intervention. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT02504216.PMID:34380322 | DOI:10.1161/CIRCULATIONAHA.121.054835
Source: Circulation - August 12, 2021 Category: Cardiology Authors: E Sebastian Debus Mark R Nehler Nicholas Govsyeyev Rupert M Bauersachs Sonia S Anand Manesh R Patel Fabrizio Fanelli Warren H Capell Taylor Brackin Franz Hinterreiter Dainis Krievins Patrice Nault Gabriele Piffaretti Alexei Svetlikov Nicole Jaeger Connie Source Type: research

Efficacy and Safety of Using Dual Versus Monotherapy Antiplatelet Agents in Secondary Stroke Prevention: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials
Conclusions: DAPT decreases the risk of recurrent stroke and composite events compared with monotherapy. DAPT increases the risk of major hemorrhage, except if the treatment is limited to 30 days and does not include the combination of aspirin plus ticagrelor.PMID:33926204 | DOI:10.1161/CIRCULATIONAHA.121.053782
Source: Circulation - April 30, 2021 Category: Cardiology Authors: Gabriela Trifan Philip B Gorelick Fernando D Testai Source Type: research

Primary Outcome Evaluation of a Next Generation Left Atrial Appendage Closure Device: Results from the PINNACLE FLX Trial
Conclusions: LAA closure with this next generation LAA closure device was associated with a low incidence of adverse events and a high incidence of anatomic closure. Clinical Trial Registration: URL https://clinicaltrials.gov Unique Identifier NCT02702271.PMID:33820423 | DOI:10.1161/CIRCULATIONAHA.120.050117
Source: Circulation - April 6, 2021 Category: Cardiology Authors: Saibal Kar Shephal K Doshi Ashish Sadhu Rodney Horton Jose Osorio Christopher Ellis James Stone Manish Shah Srinivas R Dukkipati Stuart Adler Devi G Nair Jamie Kim Oussama Wazni Matthew J Price Federico M Asch David R Holmes Robert D Shipley Nicole T Gord Source Type: research

Letter by Saleh Regarding Article, "Carotid Atherosclerosis Evolution When Targeting a Low-Density Lipoprotein Cholesterol Concentration & lt;70 mg/dL After an Ischemic Stroke of Atherosclerotic Origin"
Circulation. 2021 Mar 23;143(12):e790-e791. doi: 10.1161/CIRCULATIONAHA.120.050617. Epub 2021 Mar 22.NO ABSTRACTPMID:33750204 | DOI:10.1161/CIRCULATIONAHA.120.050617
Source: Circulation - March 22, 2021 Category: Cardiology Authors: Christian Saleh Source Type: research

Research Priorities in Atrial Fibrillation Screening: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop.
khia MP, Van Gelder IC, Cooper LS, Al-Khatib SM Abstract Clinically recognized atrial fibrillation (AF) is associated with higher risk of complications, including ischemic stroke, cognitive decline, heart failure, myocardial infarction, and death. It is increasingly recognized that AF frequently is undetected until complications such as stroke or heart failure occur. Hence, the public and clinicians have an intense interest in detecting AF earlier. However, the most appropriate strategies to detect undiagnosed AF (sometimes referred to as subclinical AF) and the prognostic and therapeutic implications of AF detect...
Source: Circulation - January 26, 2021 Category: Cardiology Authors: Benjamin EJ, Go AS, Desvigne-Nickens P, Anderson CD, Casadei B, Chen LY, Crijns HJGM, Freedman B, Hills MT, Healey JS, Kamel H, Kim DY, Link MS, Lopes RD, Lubitz SA, McManus DD, Noseworthy PA, Perez MV, Piccini JP, Schnabel RB, Singer DE, Tieleman RG, Tur Tags: Circulation Source Type: research

Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients with Atrial Fibrillation After Acute Coronary Syndrome or PCI: Insights from The AUGUSTUS Trial.
Conclusions: The safety and efficacy of apixaban was consistent irrespective of kidney function, as compared with warfarin, and in accordance with the overall trial results. The risk of bleeding with aspirin was consistently higher across all kidney function categories. Clinical Trial Registration: URL: https://www.clinicaltrials.gov Unique Identifier: NCT02415400. PMID: 33461308 [PubMed - as supplied by publisher]
Source: Circulation - January 19, 2021 Category: Cardiology Authors: Hijazi Z, Alexander JH, Li Z, Wojdyla DM, Mehran R, Granger CB, Parkhomenko A, Bahit MC, Windecker S, Aronson R, Berwanger O, Halvorsen S, de Waha-Thiele S, Sinnaeve P, Darius H, Storey RF, Lopes RD Tags: Circulation Source Type: research

Clinical Efficacy and Safety of Alirocumab after Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial.
Conclusions: After accounting for differences in baseline characteristics and adherence, patients treated with alirocumab who achieved LDL-C levels <25 mg/dL did not appear to derive further reduction in the risk of MACE compared to those who achieved LDL-C levels of 25-50 mg/dL. Clinical Trial Registration: URL: https://www.clinicaltrials.gov Unique identifier: NCT01663402. PMID: 33438437 [PubMed - as supplied by publisher]
Source: Circulation - January 13, 2021 Category: Cardiology Authors: Schwartz GG, Steg PG, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Jukema JW, Kim YU, Li QH, Manvelian G, Pordy R, Sourdille T, White HD, Szarek M, ODYSSEY OUTCOMES Committees and Investigators Tags: Circulation Source Type: research